Authorities have to consider different types of evidence. The UK Court of Appeal broadly upholds the CAT’s judgment in Phenytoin and clarifies “excessive pricing” test
Summary On 10 March 2020 the Court of Appeal upheld the Competition Appeal Tribunal’s (CAT) quashing of the Competition and Markets Authority’s (CMA) decision that Pfizer and Flynn Pharma (Flynn) had abused their dominant positions in the market by pricing their epilepsy drug unfairly. Among other aspects, the Court of Appeal broadly upheld the CAT’s…